Deep Sequencing of the T-cell Receptor Repertoire Demonstrates Polyclonal T-cell Infiltrates in Psoriasis [version 1; peer review: 2 approved]

Jamie L. Harden¹, David Hamm², Nicholas Gulati¹, Michelle A. Lowes³, James G. Krueger¹

¹Laboratory for Investigative Dermatology, The Rockefeller University, New York, NY, USA
²Adaptive Biotechnologies, Seattle, WA, USA
³Division of Dermatology, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, NY, USA

Abstract
It is well known that infiltration of pathogenic T-cells plays an important role in psoriasis pathogenesis. However, the antigen specificity of these activated T-cells is relatively unknown. Previous studies using T-cell receptor polymerase chain reaction technology (TCR-PCR) have suggested there are expanded T-cell receptor (TCR) clones in psoriatic skin, suggesting a response to an unknown psoriatic antigen. Here we describe the results of high-throughput deep sequencing of the entire αβ- and γδ- TCR repertoire in normal healthy skin and psoriatic lesional and non-lesional skin. From this study, we were able to determine that there is a significant increase in the abundance of unique β- and γ- TCR sequences in psoriatic lesional skin compared to non-lesional and normal skin, and that the entire T-cell repertoire in psoriasis is polyclonal, with similar diversity to normal and non-lesional skin. Comparison of the αβ- and γδ- TCR repertoire in paired non-lesional and lesional samples showed many common clones within a patient, and these close were often equally abundant in non-lesional and lesional skin, again suggesting a diverse T-cell repertoire. Although there were similar (and low) amounts of shared β-chain sequences between different patient samples, there was significantly increased sequence sharing of the γ-chain in psoriatic skin from different individuals compared to those without psoriasis. This suggests that although the T-cell response in psoriasis is highly polyclonal, particular γδ- T-cell subsets may be associated with this disease. Overall, our findings present the feasibility of this technology to determine the entire αβ- and γδ- T-cell repertoire in skin, and that psoriasis contains polyclonal and diverse αβ- and γδ- T-cell populations.
**Introduction**

Psoriasis vulgaris (plaque psoriasis) is a chronic, inflammatory skin disease characterized by raised, red scaly plaques (Lowes et al., 2014). It has been well established that infiltration of pathogenic T-cells plays an important role in disease pathology, particularly T-cells with the ability to produce interleukin (IL)-17 and IFN-γ (Lowes et al., 2014; Perera et al., 2012). T-cell targeting and specifically biologics targeting the T₃,17 axis, have proven to be extremely efficacious in treatment of psoriasis (Lowes et al., 2014). However, despite the established role of T-cells in psoriasis pathogenesis, the potential auto-antigens eliciting disease or the antigen specificity of T-cells contributing to psoriasis are relatively unknown.

High-throughput sequencing of the T-cell receptor (TCR) repertoire can help elucidate whether a narrow subset of T-cells have undergone clonal expansion, potentially elicited by a particular antigen. Previous evaluation of TCR repertoire in psoriasis has shown preferential usage of particular β-chain variable gene segments (Chang et al., 1995; Menssen et al., 1995). However in these studies, a small number of TCR sequences was obtained from a potentially vast underlying diversity of TCR sequences (Robins et al., 2009) and clonal expansion was determined only in the context of particular Vβ-chain usages. Recent advances in next generation deep sequencing have enabled the quantitative sampling of a significantly larger enough fraction of the T-cell repertoire to make strong inferences regarding the diversity of the T-cell repertoire and measure the degree of oligoclonality based on individual clone lineages (Robins, 2013).

Here we present the first exploration of TCR deep sequencing in psoriatic (both lesional and non-lesional) and normal skin using the ImmunoSEQ assay (Adaptive Biotechnologies, Seattle, WA, USA). Genomic DNA (gDNA) and complementary DNA (cDNA) from skin of normal volunteers, as well as non-lesional and lesional skin from psoriatic patients, were used for deep sequencing of the β-chain and γ-chain, respectively. From these initial studies, we were able to fully characterize the TCR repertoire of each sample, and compare diseased and healthy skin both between and within an individual patient.

**Methods**

**Skin samples**

Normal skin biopsies from healthy volunteers (n=7), and non-lesional (n=5) and lesional skin (n=8) from patients with psoriasis, were obtained under Rockefeller University Institutional Review Board-approved protocols (IRB numbers MLO-0651 and IKR-0742), and stored in a cryovial in liquid nitrogen until use. Written informed consent was obtained and the study was performed in adherence with the Declaration of Helsinki. Data regarding patient demographics is found in Table S1. All psoriasis samples were obtained from patients with moderate-to-severe disease, which was determined by a psoriasis area severity index (PASI score) of more than 12 (moderate-to-severe psoriasis vulgaris with >10% body surface area involvement).

**Nucleic acid isolation**

Frozen skin biopsies were processed in 1mL of RLT buffer (Qiagen, Venlo, Limburg) with 1% β-mercaptoethanol, through several rounds of homogenization (Polytron PT-10-35 GT-Kinematica) and sonication (Sonic Vibra cell; model VCX130). In brief, samples were homogenized for several 30-second intervals until the sample was significantly disrupted; samples were then sonicated for 6 pulses of 1–2 seconds (at an amplitude of 80–100) to fully lyse the cells. Genomic DNA and RNA was isolated using the Qiagen All-Prep DNA/RNA/Protein kit (Qiagen, Venlo, Limburg) (Catalog number 800004), following the manufacturer’s instructions. In brief, cell lysate was added to a DNA binding column and centrifuged. The flow-through containing RNA and protein was then added to a separate RNA binding column and centrifuged. Each column containing either the DNA or RNA from a sample was then washed and the appropriate nucleic acid was eluted, according to manufactures instructions.

**Deep sequencing**

6–8μg of genomic DNA (at a concentration of 50ng/μl), was used for survey level deep sequencing of the β-chain, using the ImmunoSEQ platform (Adaptive Biotechnologies, Seattle, WA, USA). 2μg of RNA was used for reverse transcription using the High Capacity cDNA Reverse Transcriptase Kit (Applied Biosystems, Carlsbad, CA) (Catalog number 4368814), according to manufacturer’s protocols, and the entirety of the cDNA reaction was sent to Adaptive biotechnologies for survey level deep sequencing of the γ-chain using the ImmunoSEQ platform. Details of the deep sequencing assay are as follows: the TCRβ and TCRγ CD3 region was amplified and sequenced using the ImmunoSEQ assay (Adaptive Biotechnologies, Seattle, WA). In this assay, a multiplex PCR system was used to amplify the rearranged CDR3β and CDR3γ sequences from sample DNA or cDNA, respectively. The 87-base-pair fragment is sufficient to identify the VDJ region spanning each unique CDR3β. Amplicons were sequenced using the Illumina platform. TCRβ and TCRγ V, D and J gene definitions were provided by the IMGT database (www.imgt.org). The assay is quantitative, having used a complete synthetic repertoire of TCRs to establish an amplification baseline and adjust the assay chemistry to correct for primer bias. In addition, barcoded, spiked-in synthetic templates were used to measure the degree of sequencing coverage and residual PCR bias. This information was used for further PCR bias correction and to estimate the abundance of sequenceable templates in each sample. The resulting data is filtered and clustered using both the relative frequency ratio between similar clones and a modified nearest-neighbor algorithm, to merge closely related sequences and remove both PCR and sequencing errors. Data was analyzed using the ImmunoSEQ analyzer toolset, as further described below.

**Data analysis**

Sequencing data were analyzed using the immunoSEQ Analyzer (https://clients.adaptivebiotech.com/login). Entropy H (i.e. Shannon’s Entropy), is a measure of the richness and uniformity of the TCR repertoire’s frequency distribution

\[ H = - \sum_{i=1}^{N} P_i \log_2 P_i, \]

in which N is the number of unique clones and P is the frequency of clone i. Entropy ranges from 0 in a sample with only one clone, to \( H_{\text{max}} = \log_2 N \) for a sample with a uniform distribution of clone
frequencies. Monoclonal or oligoclonal samples have low entropy, and polyclonal highly diverse samples have entropy just under $\log_2 N$. The measurement of entropy is sensitive to sampling depth, as sample size is the primary driver of the number of unique sequences in a sample. To account for variation in sequencing depth, entropy is normalized by its maximum value to give a metric that measures just sample evenness.

$$H_N = \frac{H}{H_{\text{max}}}.$$  

Clonality (Sherwood et al., 2013) is defined as $C = 1 - H_N$. Clonality equals 0 when all sequences are equally abundant, and equals 1 when a single sequence makes up the entire sample. Overlap scores (Figure 3) excluded all paired non-lesional (NL) and lesional (LS) psoriatic skin comparisons were removed to prevent artificial inflation of the NL-LS comparison group. All data was analyzed using an unpaired students t-test or ANOVA, using the GraphPad Prism5 software. Error bars represent the standard error of the mean. P-values < 0.05 were considered significant.

**Results**

Dataset 1. Raw data for “Deep Sequencing of the T-cell Repertoire Demonstrates Polyclonal T-cell Infiltrates in Psoriasis”

http://dx.doi.org/10.5256/f1000research.6756.d97231

Deep sequencing identifies an average of $2.7 \times 10^3$ unique TCRβ-CDR3 (complementarity-determining region 3) sequences in normal skin, $3.2 \times 10^3$ unique TCRβ-CDR3 in non-lesional skin, and an average of $10.9 \times 10^3$ unique TCRβ-CDR3 sequences in psoriatic lesional skin, a significant three-fold increase compared to both normal ($p = 0.0127$) and non-lesional ($p = 0.0295$) skin (Figure 1a). The number of unique sequences was also significantly increased ($p = 0.0159$) approximately three-fold for the γ-chain, with an average of 397 unique TCRγ-CDR3 sequences in normal skin, 558 unique TCRγ-CDR3 in non-lesional skin, and an average of $1.57 \times 10^3$ unique TCRγ-CDR3 sequences in psoriatic lesional skin (Figure 1b). The observation that there were more productive unique sequences in psoriatic skin is most likely a consequence of the increased numbers of T-cells well-known to occur in this disease (Lowes et al., 2014; Zaba et al., 2007).

Clonality was used to compare the degree of clonal expansion across groups of samples. Psoriatic skin (both non-lesional and lesional) had slightly less clonality in the β-chain (i.e. more diverse and polyclonal population) than normal skin; however this finding was not statistically significant ($p = 0.1255$ for normal versus lesional; $p = 0.1419$ for non-lesional versus lesional) (Figure 1c). The clonality of the γ-chain repertoire was very similar between normal, non-lesional and lesional psoriatic skin (Figure 1d). Therefore, in combination with a clear signal of increased numbers of T-cells in psoriatic tissue, this suggests that the increase in T-cells is not

*Figure 1. Psoriatic lesional skin has an increased number of unique TCRβ and TCRγ sequences and is not more clonal than normal and non-lesional skin. The total number of unique (a) β- and (b) γ-chain CDR3 sequences, and the clonality of the entire (c) β- and (d) γ-chain repertoire (y-axis) in normal and psoriatic lesional and non-lesional skin (x-axis). Error bars represent standard error of the mean. Statistics were performed using an unpaired t-test. * $p < 0.05.$*
due to the clonal expansion of a limited number of disease specific T-cells but the infiltration of large and diverse numbers of both αβ- and γδ- T-cells responding to an immune signaling cascade.

Similar usage of variable (V) and joining (J) genes in both the β- and γ-chains of all samples

The variable (V) and joining (J) gene usage of both the β- and γ-chains was compared across the normal, non-lesional, and lesional psoriatic skin groups (Figure S1). Previous studies have suggested significant variations in V- and J- gene usage between normal and psoriatic skin. Although we found trends supporting these previous observations, such as TCRVβ02.1 preferentially utilized in normal skin (Chang et al., 1995; Menssen et al., 1995), much larger sample sizes would be required to verify potential gene usage differences.

Clones in lesional skin are found in paired non-lesional skin at similar percentages

To determine if the most abundant clones in lesional skin may expand from a rare subset in non-lesional skin, we compared the β- and γ-chain TCR repertoire in paired lesional and non-lesional samples (Figure 2). Although there were many clones uniquely present in only non-lesional and lesional skin, in all patients the most abundant clones in lesional skin were also the most abundant in non-lesional skin. This suggests that the abundance of clones in lesional skin is not the result of the expansion of a rare-subset in non-lesional skin, but is rather a general expansion and/or influx of many clones.

Common sequences are found in the γ-chain repertoire of psoriatic skin

Although there is a highly diverse and polyclonal T-cell response in psoriasis, with no clear enrichment for particular variable (V) and joining (J) genes, there may still be clones specifically associated with psoriatic skin. If this is correct, it would be expected then that the degree of pair-wise sequence sharing would be greater within the psoriatic group. To test this hypothesis, the fraction of shared sequences between all pair-wise sets of samples was calculated (Figure 3). There was no significant difference (ANOVA p = 0.1114) in the overlap score for any comparisons of the β-chain (Figure 3a). However, there were significant differences in overlap score comparisons for the γ-chain (ANOVA p = 0.0039) (Figure 3b). The psoriatic lesional skin γ-chain repertoire exhibited significantly more pair-wise overlap than healthy controls. Additionally, the γ-chain repertoire of non-lesional skin compared to psoriatic skin contained significantly more overlap than comparison of non-lesional skin to normal skin. This finding suggests that unique populations of cutaneous γδ- T-cells may be present in psoriatic patients.

To further assess this hypothesis, we explored if there were any common TCRγ sequences between all of the samples within a group. There were no common γ-chain sequences among all the normal samples. However, there were 3 common γ-chain sequences found among all psoriatic lesional skin samples (Figure 3c). Additionally, one of those γ-chain sequences was also found in all non-lesional skin samples as well. Regarding the β-chain, no common sequences were found in any group.

Discussion

We have utilized the recent advances in next-generation sequencing to provide evidence for diverse and polyclonal αβ- and γδ- T-cell populations in psoriasis lesional skin. Although several previous studies have focused on the clonality within a range of Vβ- usages (Chang et al., 1995; Menssen et al., 1995; Vollmer et al., 2001), this is the first time sufficient numbers of sequences have been obtained to fully characterize the diversity of the TCR repertoire in psoriasis. We found that although lesional skin contained significantly more unique β- and γ- chain sequences than normal and non-lesional skin, lesional skin was highly polyclonal with no dominant T-cell clones. This finding supports a diverse and non-specific polyclonal T-cell infiltrate in psoriasis lesional skin.

Based on previous work, it may have been anticipated that there would be higher clonality compared to control samples, due to expansion of T-cells to an unknown antigen. The first gene associated with psoriasis (located at PSORS1) is HLA-Cw6 (Perera et al., 2012); it was thought that HLA-Cw6 likely predisposes to psoriasis by presentation of an unknown autoantigen. Mutations in other immune-related genes have recently been found to impose psoriasis-susceptibility, such as IL-36RN and CARD14 (Jordan et al., 2012; Marrakchi et al., 2011); however the immunological activities of these latter genes are not solely at the adaptive immune level, and play important roles in general inflammation.

Several previous studies utilizing TCR-PCR technology found the same clones present in lesional skin of a patient over time (Chang et al., 1995; Menssen et al., 1995; Vollmer et al., 2001), and these clones were absent in non-lesional skin. In our study, we found that the most prevalent clones in lesional skin were present at a similar amount (percent of reads) in non-lesional skin. Our data suggests that it is not an expansion of common non-lesional/lesional clone as the driver of psoriasis, but rather a general polyclonal T-cell expansion in psoriatic lesional skin.

Although αβ-T-cells are more prevalent than γδ T-cells in human skin (Elbe et al., 1996), it has recently been appreciated that γδ T-cells may contribute to psoriatic inflammation, as they can be major producers of IL-17, a key cytokine in psoriasis pathogenesis (Cai et al., 2012). We found minimal similarities between the TCRβ-repertoire of different patient samples despite the much greater sample sizes of TCRβ clones. However, three common TCRγ clones were found in all lesional skin samples, and one clone was found in all non-lesional and lesional skin, but was absent in normal skin. This finding merits further investigation with larger samples sizes to determine if particular γδ- T-cells are common among psoriasis patients and may represent a population(s) responding to a similar antigen(s).

In conclusion, we have provided the first deep sequencing results of the entire β- and γ- T-cell repertoire in normal, non-lesional, and lesional human skin. Our findings demonstrate highly polyclonal αβ- and γδ- T-cell populations in psoriasis lesional skin, with the most common clones being present in both non-lesional and lesional skin. Lastly, there may be possible contributions of specific γδ- T-cell in psoriasis, as evidenced by common CDR3 sequences between patients.
Figure 2. Common clones maintain similar frequency between non-lesional and lesional skin. Comparison of TCR (left) β- and (right) γ-chain CDR3 sequences in paired non-lesional and lesional psoriasis samples. Each dot represents one clone and the percent of total reads of a given clone in non-lesional (y-axis) and lesional (x-axis) skin are shown. Clones uniquely in non-lesional skin are located on the y-axis in red; clones uniquely in lesional skin are located on the x-axis in green; and clones found in both non-lesional and lesional skin are in blue. The absolute number of sequences in only non-lesional (red), only lesional (green), or both (blue) are located under each graph.
Figure 3. Increased sharing of TCRγ are found in psoriatic skin. Sequence similarity overlap scores (y-axis) obtained from the comparisons, normalized to total number of sequences and pooled into common groups (x-axis) for the (a) β- and (b) γ-chain. (c) Common clones found within all lesional psoriatic skin samples (top), and one clone found in all psoriatic lesional and non-lesional skin (bottom). Error bars represent standard error of the mean. Statistics were performed using an unpaired t-test. * p < 0.05.

Data availability
F1000Research: Dataset 1. Raw data for “Deep Sequencing of the T-cell Receptor Repertoire Demonstrates Polyclonal T-cell Infiltrates in Psoriasis”, 10.5256/f1000research.6756.d97231 (Harden et al., 2015).

This data is also available from the Adaptive Biotechnology ImmunoSEQ site (http://adaptivebiotech.com/pub/Harden-2015-F1000Res) which provides access to ImmunoSEQ Analyzer and other tools used for analyses.

Author contributions
JLH, MAL, and JGK conceived the study and designed the experiments. JLH and NG carried out the research. DH provided essential expertise in data analysis. JLH, MAL and DH prepared the first draft of the manuscript. All authors were involved in the revision of the manuscript and have agreed to the final content.

Competing interests
All authors state no conflict of interest. DH has employment and stock options at Adaptive Biotechnologies.

Grant information
This research was made possible by The American Skin Association Research Grant and Adaptive Biotechnologies Young Investigator Award, both awarded to JLH. MAL and JLH were supported by NIH 1R01AR060222.

I confirm that the funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Acknowledgements
We would like to thank Dr. Catherine Sanders (Adaptive Biotechnologies) for project consultation, Dr. Dáibhid Ó Maoiléidigh for assistance in manuscript preparation and interpretation of data, and Mary M. Sullivan-Whalen for acquiring biopsies for this study.

Supplementary material
Supplementary material for “Deep Sequencing of the T-cell Receptor Repertoire Demonstrates Polyclonal T-cell Infiltrates in Psoriasis”. Click here to access the data
References

Cai Y, Fleming C, Yan J: New insights of T cells in the pathogenesis of psoriasis. Cell Mol Immunol. 2012; 9(4): 302–9. PubMed Abstract | Publisher Full Text

Chang JC, Smith LR, Froning KJ, et al.: CD8+ T-cells in psoriatic lesions preferentially use T-cell receptors V beta 3 and/or V beta 13.1 genes. Ann N Y Acad Sci. 1995; 756: 370–81. PubMed Abstract | Publisher Full Text

Elbe A, Foster CA, Stingl G: T-cell receptor alpha beta and gamma delta T cells in rat and human skin--are they equivalent? Semin Immunol. 1996; 8(6): 341–9. PubMed Abstract | Publisher Full Text

Harden J, David H, Gulati N, et al.: Dataset 1 in: Deep Sequencing of the T-cell Receptor Repertoire Demonstrates Polyclonal T-cell Infiltrates in Psoriasis. F1000Research. 2015. Data Source

Jordan CT, Cao L, Roberson ED, et al.: PSORS2 is due to mutations in CARD14. Am J Hum Genet. 2012; 90(5): 784–96. PubMed Abstract | Publisher Full Text | Free Full Text

Lowes MA, Suárez-Fariñas M, Krueger JG: Immunology of psoriasis. Annu Rev Immunol. 2014; 32: 227–55. PubMed Abstract | Publisher Full Text | Free Full Text

Marrack S, Guigue P, Renshaw BR, et al.: Interleukin-36 receptor antagonist deficiency and generalized pustular psoriasis. N Engl J Med. 2011; 365(7): 620–8. PubMed Abstract | Publisher Full Text

Menssen A, Trommler P, Vollmer S, et al.: Evidence for an antigen-specific cellular immune response in skin lesions of patients with psoriasis vulgaris. J Immunol. 1995; 155(8): 4078–83. PubMed Abstract

Perera GK, Di Meglio P, Nestle FO: Psoriasis. Annu Rev Pathol. 2012; 7: 385–422. PubMed Abstract | Publisher Full Text

Robins H: Immunosequencing: applications of immune repertoire deep sequencing. Curr Opin Immunol. 2013; 25(5): 646–52. PubMed Abstract | Publisher Full Text

Robins HS, Campregar PV, Silvastava SK, et al.: Comprehensive assessment of T-cell receptor beta-chain diversity in alpha-beta T cells. Blood. 2009; 114(19): 4099–107. PubMed Abstract | Publisher Full Text | Free Full Text

Sherwood AM, Emerson RO, Scherer D, et al.: Tumor-infiltrating lymphocytes in colorectal tumors display a diversity of T cell receptor sequences that differ from the T cells in adjacent mucosal tissue. Cancer Immunol Immunother. 2013; 62(9): 1453–61. PubMed Abstract | Publisher Full Text

Vollmer S, Menssen A, Prinz JC: Dominant lesional T cell receptor rearrangements persist in relapsing psoriasis but are absent from nonlesional skin: evidence for a stable antigen-specific pathogenic T cell response in psoriasis vulgaris. J Invest Dermatol. 2001; 117(5): 1296–301. PubMed Abstract | Publisher Full Text

Zaba LC, Cardinale I, Gilleaudeau P, et al.: Amelioration of epidermal hyperplasia by TNF inhibition is associated with reduced Th17 responses. J Exp Med. 2007; 204(13): 3183–94. PubMed Abstract | Publisher Full Text | Free Full Text
Open Peer Review

Current Peer Review Status: ✔ ✔

Version 1

Reviewer Report 09 September 2015

https://doi.org/10.5256/f1000research.7258.r10142

© 2015 Yan J et al. This is an open access peer review report distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Jun Yan
Department of Microbiology and Immunology, School of Medicine, University of Louisville, Louisville, KY, USA

Yihua Cai
Department of Microbiology and Immunology, School of Medicine, University of Louisville, Louisville, KY, USA

The manuscript by Harden et al. entitled “Deep Sequencing of the T cell Receptor Repertoire Demonstrates Polyclonal T-cell Infiltrates in Psoriasis” describes the results of high-throughput deep sequencing of the TCR beta and gamma chains in normal healthy skin and psoriatic lesional and nonlesional skin tissues. The authors found that although there is a significant increase in the abundance of unique beta and gamma TCR sequences in psoriatic lesional skin, the entire T cell repertoire in psoriasis is polyclonal. More strikingly, they found three common sequences of gamma chain repertoire in psoriatic skin. These are really exciting findings and provide novel insights into understanding psoriasis immunopathogenesis.

Minor comments:
1. The rationale for using genomic DNA (gDNA) for TCR beta chain while cDNA for TCR gamma chain sequencing needs to be clearly delineated. This is particularly important given the fact that different target enrichment solutions have its own pros and cons.

2. The authors conclude that the entire T cell repertoire in psoriasis is rather polyclonal with similar diversity in normal vs non-lesional skin, which is contradictory to previous reports. The authors may want to discuss this further, e.g. whether this discrepancy is due to different technology used or other factors.

3. Were psoriatic lesional and non-lesional skin tissues paired?

Competing Interests: No competing interests were disclosed.
We confirm that we have read this submission and believe that we have an appropriate level of expertise to confirm that it is of an acceptable scientific standard.

Reviewer Report 08 September 2015

https://doi.org/10.5256/f1000research.7258.r10141

© 2015 Eidsmo L et al. This is an open access peer review report distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Liv Eidsmo
Unit of Dermatology and Venereology, Department of Medicine, Karolinska Institutet, Solna, Sweden

Stanley Cheuk
Unit of Dermatology and Venereology, Department of Medicine, Karolinska Institutet, Solna, Sweden

Harden et al., provide the first deep sequence analysis of the T cell receptor in lesional and non-lesional skin collected from psoriasis patients. The authors simultaneously track and quantify of the V-β (from DNA) and V-γ (from RNA) T cell receptor within the same skin tissue samples. The data suggest that the T cell infiltrate in full-thickness psoriasis lesions is clonally diverse and the authors could not reproduce previous results showing oligoclonal expansion of TCR ab within the skin. The authors do however suggest clonal enrichment of TCR γ in psoriasis patients, both in lesional and non-lesional skin, in comparison to healthy skin. The manuscript is straightforward but there are several points that the authors could comment or discuss further as listed below.

Major concerns:
1. The majority of infiltrating T cells in psoriasis are found in the dermal compartment of the skin with only a small population of T cells infiltrating epidermis. However, an enrichment of pathogenic IL-17 and IL-22 producing T cells in epidermis as compared to dermis of psoriasis has been shown in a number of reports (Res et al., 2010; Hijn en et al., 2013; Cheuk et al., 2014). Of interest, the oligoclonal T cell expansion shown by Menssen et al. (1995) in the same psoriasis plaques over time were detected in epidermis and intraepithelial oligoclonal T cell expansion was also suggested by Lin et al. (2001). Without dissecting epidermis and dermis, it is difficult to draw the conclusion that psoriasis is a “highly polyclonal” response lacking oligo-cloneal expansion.

2. Intraindividual comparison of two lesional and two non-lesional samples would be interesting to determine the heterogeneity of T cell infiltration in different sites of inflamed and non-affected skin.

3. Please comment on the skewed ethnicity between the healthy controls and the patient group analyzed. Could this affect the interpretation of the γδ data, in which the authors showed overlap among NL and LS as compared to the controls?
4. Did quantification of TCRg analysed in RNA or DNA give identical results or was a bias in the quantification introduced when analysing cDNA?

5. Figure 3: How the overlap score is calculated is unclear. Is that equivalent to “the fraction of shared sequences between all pair-wise sets of samples”? A more detail description will be appreciated.

**Minor points:**
- Abstract row 14: “…these close were often…” should probably read “…these clones were often…”.
- Figure 2: Out of 5 donors, 2 (or 3) did not show much difference in the total number of unique sequences between NL and LS. That was inconsistent with data from figure 1. Please comment on that.
- The sharing of specific TCRγ clones among different patients but absent in healthy controls is intriguing. Are these clones consistent with the infiltrating gd T cells in psoriasis described by Laggner et al. (2011)
- Figure 3: Were the pair-wised comparison from the same donor omitted or included in the calculation since some of the LS and NL were collected from the same donor? That would affect the interpretation statistical testing between the groups concerning the healthy control and the groups concerning only psoriasis patients. Please comment on that.
- Figure 3: The overlapping score or fraction of shared sequences between different donors in the case of TCR-β is difficult to interpret since the donor HLA type is not shown.

**Competing Interests:** No competing interests were disclosed.

We confirm that we have read this submission and believe that we have an appropriate level of expertise to confirm that it is of an acceptable scientific standard.
The benefits of publishing with F1000Research:

• Your article is published within days, with no editorial bias
• You can publish traditional articles, null/negative results, case reports, data notes and more
• The peer review process is transparent and collaborative
• Your article is indexed in PubMed after passing peer review
• Dedicated customer support at every stage

For pre-submission enquiries, contact research@f1000.com